UNITED THERAPEUTICS (UTHR) EVP & counsel exercises options and sells 8,300 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares of Common Stock in pre-planned trades. On May 21, 2026, the EVP & General Counsel exercised options covering 8,300 shares at a conversion price of $146.03 per share and sold 8,300 shares in multiple open-market transactions at weighted-average prices in the mid-$560s. These trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the transactions, Mahon directly holds 45,172 shares of UNITED THERAPEUTICS Common Stock.
Positive
- None.
Negative
- None.
Insights
Routine 10b5-1 option exercise and sale, modest informational signal.
EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of UNITED THERAPEUTICS Common Stock at a conversion price of $146.03 on May 21, 2026. He sold 8,300 shares the same day in multiple open-market trades, with reported weighted-average prices around the mid-$560s.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025, indicating they were scheduled in advance rather than timed opportunistically. Following the transactions, Mahon directly holds 45,172 shares of Common Stock, suggesting he retains a meaningful equity stake while converting an option grant into cash.
Because the actions combine a derivative exercise with offsetting sales under a pre-planned program, they are typically viewed as part of ongoing compensation and liquidity management rather than a major change in insider positioning. Subsequent filings will show any further activity under this 10b5-1 plan.
Insider Trade Summary 10b5-1
Net Seller: 8,300 shares ($4,671,399)
Net Sell
13 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.67M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,300 | $0.00 | -- |
| Exercise | Common Stock | 300 | $146.03 | $44K |
| Exercise | Common Stock | 8,000 | $146.03 | $1.17M |
| Sale | Common Stock | 110 | $555.7213 | $61K |
| Sale | Common Stock | 10 | $556.70 | $6K |
| Sale | Common Stock | 640 | $557.85 | $357K |
| Sale | Common Stock | 200 | $559.99 | $112K |
| Sale | Common Stock | 2,178 | $561.9902 | $1.22M |
| Sale | Common Stock | 1,326 | $562.9331 | $746K |
| Sale | Common Stock | 2,015 | $564.0563 | $1.14M |
| Sale | Common Stock | 1,251 | $565.1951 | $707K |
| Sale | Common Stock | 270 | $566.053 | $153K |
| Sale | Common Stock | 300 | $562.50 | $169K |
Holdings After Transaction:
Stock Option — 113,940 shares (Direct, null);
Common Stock — 45,472 shares (Direct, null)
Footnotes (1)
- This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. This transaction was executed in multiple trades at prices ranging from $555.56 to $556.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $561.31 to $562.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $562.63 to $563.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.77 to $564.755. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.905 to $565.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.91 to $566.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 8,300 shares
Shares exercised: 8,300 shares
Exercise price: $146.03 per share
+4 more
7 metrics
Shares sold
8,300 shares
Open-market sales of Common Stock on May 21, 2026
Shares exercised
8,300 shares
Stock options converted to Common Stock on May 21, 2026
Exercise price
$146.03 per share
Stock option conversion price
Post-transaction holdings
45,172 shares
Common Stock directly held after transactions
Sale price example
$562.50 per share
One reported open-market sale price
Sale price example
$566.053 per share
Another reported open-market sale price
Sale price example
$561.9902 per share
Reported weighted-average sale price in one trade
Key Terms
Rule 10b5-1 trading plan, stock options, open-market sale, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan financial
"pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did UTHR executive Paul A. Mahon report on May 21, 2026?
Paul A. Mahon reported exercising stock options for 8,300 UNITED THERAPEUTICS shares and selling 8,300 Common Stock shares. The sales occurred in multiple open-market trades at weighted-average prices in the mid-$560s, converting an option award into cash while maintaining a significant remaining share position.
Were Paul A. Mahon’s UTHR stock sales made under a Rule 10b5-1 plan?
Yes. The footnotes state the exercise of stock options and subsequent sale of resulting UNITED THERAPEUTICS shares were executed under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025, indicating these trades were scheduled in advance.
What prices were reported for Paul A. Mahon’s UTHR stock sales on May 21, 2026?
The Form 4 reports multiple open-market sales of UNITED THERAPEUTICS Common Stock on May 21, 2026 at weighted-average prices generally in the mid-$560s per share. Several trades were executed within disclosed ranges around $555–$566 according to the transaction footnotes.
What was the stock option exercise price in Paul A. Mahon’s UTHR Form 4 filing?
The stock options exercised by Paul A. Mahon on May 21, 2026 carried a conversion or exercise price of $146.03 per share. Exercising these options and selling resulting shares monetized a prior equity award while leaving him with 45,172 shares of UNITED THERAPEUTICS Common Stock.
Does the May 21, 2026 UTHR Form 4 show new option grants to Paul A. Mahon?
No new option grants are described. The filing details the exercise of existing stock options covering 8,300 shares at a $146.03 exercise price and the sale of 8,300 Common Stock shares in open-market trades, rather than any fresh option awards.